Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 94Thoracic 77Other hematologic neoplasm 52CNS 25Sarcoma 13Other solid neoplasm 12Genitourinary 12Plasma cell 7Myeloid 6Endocrine 6Dermatologic 5Gastrointestinal 3NET 2Head & Neck 2Gynecologic 2Classical hematology 2Other neoplasm 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 29Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5olaparib 4lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4copper dotatate CU-64 3atezolizumab 3Temozolomide 3Ga(III)-DOTATOC 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Etoposide × NET × 1 year × Clear all
NCT06406465 2026-05-27

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
83 enrolled 13 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡